- Related Products
MedEx answers any queries you might have regarding Sutent-25 purchase, shipping and payment terms.
Feel free to contact support through inquiry form, MedeEx is fully dedicated towards your needs 24/7.
Indications for use.
Sutent 25 mg is intended for the treatment of gastrointestinal stromal tumor (if the treatment with imatinib was ineffective, or in case of hypersensitivity or resistance, to this active substance).
Sutent can be prescribed to the patients with untreated metastatic or locally advanced renal cell cancer (or if cytokine therapy was unsuccessful).
Way of use.
Sutent should be taken orally, irrespective of the mealtime. Take the capsules with adequate amount of liquid.
Dosage and duration of treatment must be determined by the specialist. Therapy with Sutent 25 mg must be conducted by the health professional, experienced in treating the patients with anti-cancer drugs.
Initial dose of Sutent is 25 mg a day. The drug must be taken for 4 weeks, after which you should take a 2-week break. The full treatment cycle is 6 weeks (4 weeks of treatment and 2 weeks of break).
If you skipped the dose of Sutent 25 mg, you shouldn’t double the next dose.
During the treatment, the patient must be supervised by the health professional who will correct the dose if necessary. Usually, the dose should be increased/reduced by no more than 12.5 mg at a time.
Maximum daily dose of Sunitinib – 87.5 mg.
Minimum daily dose of Sunitinib – 12.5 mg.
Older patients and people with moderate kidney failure (if is creatinine level is more than twice the upper border), the dosage correction isn´t necessary.
Patients with liver dysfunction (high level of AST/ALT no more than 2.5 times the upper border; or in case of the existent high AST/ALT no more than five times the upper border), the dosage correction isn’t required.
At the beginning of each cycle of treatment with Sutent 25 mg, you should control your hematological indices.
Patient using Sutent must periodically visit the cardiologist to ensure the early detection of congestive heart failure.
If you notice the symptoms of congestive heart failure, you should temporarily withdraw Sunitinib. The treatment can be resumed only after consulting the specialist who will decide whether you should continue the treatment course.
Patients with hyperthyroidism or hypothyroidism (and even those who haven’t had any thyroid problems before) should periodically monitor thyroid function.
Before and during the treatment you should monitor the kidney function. In case of nephrotic syndrome, therapy with Sutent 25 mg should be cancelled.